GILD
GILEAD SCIENCES, INC.
(NASDAQ: GILD)
Balfour Capital Group has issued a buy recommendation
for Gilead Sciences, Inc. (GILD) on November 23th, 2023
Gilead Sciences, Inc., headquartered in Foster City, California, is an American biopharmaceutical company focused on antiviral drugs for HIV/AIDS, hepatitis B and C, influenza, and COVID-19. Founded in 1987 as Oligogen, it developed notable drugs like Tamiflu and Vistide and evolved into a major pharmaceutical company.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $75.89 on November 23th, 2023.
- Our designated price target stands at $104.00
- With our $104.00 target met, we are confidently raising our outlook to $143.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q3 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Gilead Sciences, Inc. (GILD) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
ALNY
ALNYLAM PHARMACEUTICALS, INC.
(NASDAQ: ALNY)
Balfour Capital Group has issued a buy recommendation for Alnylam Pharmaceuticals, Inc. (ALNY) on Nov. 26th, 2023.
Alnylam Pharmaceuticals, Inc., founded in 2002 and headquartered in Cambridge, Massachusetts, is an American biopharmaceutical company specializing in RNA interference (RNAi) therapeutics for genetically defined diseases. In 2016, Forbes recognized it as one of the “100 Most Innovative Growth Companies.”
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $162.98 on November 26th, 2023.
- Our designated price target stands at $300.00
- With our $300.00 target met, we are confidently raising our outlook to $412.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Alnylam Pharmaceuticals, Inc. (ALNY) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
ABBV
ABBVIE INC.
(NYSE: ABBV)
Balfour Capital Group has issued a buy recommendation
for Abbvie Inc. (ABBV) on November 26th, 2023
AbbVie Inc. is a global, research-based biopharmaceutical company that discovers, develops, manufactures, and sells a broad range of innovative medicines and therapies. The company’s product portfolio spans several key therapeutic areas, including immunology, oncology, neuroscience, eye care, virology, and women’s health. AbbVie was established in 2013 as a spin-off from Abbott Laboratories and is headquartered in North Chicago, Illinois.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $138.70 on November 26th, 2023.
- Our designated price target stands at $196.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Abbvie Inc. (ABBV) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
DOV
DOVER CORPORATION.
(NYSE: DOV)
Balfour Capital Group has issued a buy recommendation for Dover Corporation. (DOV) on November 26th, 2023
Dover Corporation, headquartered in Downers Grove, Illinois, is an American conglomerate manufacturer of industrial products. Founded in 1955, it operates in five segments: Engineered Products, Clean Energy and Fueling, Imaging & Identification, Pumps & Process Solutions, and Climate and Sustainability Technologies. Dover trades on the NYSE under “DOV.”
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $139.68 on November 26th, 2023.
- Our designated price target stands at $230.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors.
Balfour Capital Group wants to clarify that our recommendation to Buy Dover Corporation (DOV) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
PPG
PPG INDUSTRIES, INC.
(NYSE: PPG)
Balfour Capital Group has issued a buy recommendation
for PPG Industries, Inc. (PPG) on December 1st, 2023
PPG Industries, Inc., headquartered in Pittsburgh, Pennsylvania, is a global supplier of paints, coatings, and specialty materials. Operating in over 70 countries, it is the largest coatings company by revenue. PPG’s headquarters, PPG Place, features a glass facade designed by architect Philip Johnson.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $143.63 on December 1st, 2023.
- Our designated price target stands at $185.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy PPG Industries, Inc. (PPG) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
NTRS
NORTHERN TRUST CORPORATION
(NASDAQ: NTRS)
Balfour Capital Group Researched Northern Trust Corporation (NTRS) on December 8th, 2023.
Northern Trust Corporation is a financial holding company that provides wealth management, asset servicing, asset management, and banking solutions for corporations, institutions, families, and individuals worldwide. Founded in 1889 and headquartered in Chicago, Illinois, the company operates through two main segments: Asset Servicing and Wealth Management. As of March 31, 2023, Northern Trust had $1.3 trillion in assets under management and $14.2 trillion in assets under custody.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $80.46 on December 8th, 2023.
- Our designated price target stands at $125.00
- With our $125.00 target met, we are confidently raising our outlook to $162.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy NORTHERN TRUST CORPORATION (NTRS) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
COST
COSTCO WHOLESALE CORPORATION
(NASDAQ: COST)
Balfour Capital Group Researched Costco Wholesale Corporation (COST) on December 11th, 2024.
Costco Wholesale Corporation operates an international chain of membership warehouses, mainly under the “Costco Wholesale” name, that carry quality, brand-name merchandise at substantially lower prices than are typically found at conventional wholesale or retail sources.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $610.00 on December 11th, 2023.
- Our designated price target stands at $1200.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q2 EARNING REPORT
A Q2 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy COSTCO WHOLESALE CORPORATION (COST) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
NTSE
WisdomTree Emerging Markets Efficient Core Fund
(NTSE)
Balfour Capital Group Researched WisdomTree Emerging Markets Efficient Core Fund (NTSE) on December 12th, 2023.
The WisdomTree Emerging Markets Efficient Core Fund is an exchange-traded fund (ETF) that seeks total return by investing in emerging markets equity securities and U.S. Treasury futures contracts. The fund aims to provide enhanced exposure to emerging market equities while utilizing bond futures diversification to potentially lower volatility. This strategy is designed to boost capital efficiency in asset allocation, allowing for increased exposure to non-core or diversifying investments.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $26.90 on December 12th, 2023.
- Our designated price target stands at $150.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy WisdomTree Emerging Markets Efficient Core Fund (NTSE) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
JNJ
JOHNSON & JOHNSON
(NYSE: JNJ)
Balfour Capital Group Researched Johnson & Johnson (JNJ) on December 13th, 2023.
Johnson & Johnson is a multinational corporation specializing in the research, development, manufacture, and sale of a broad range of healthcare products. The company operates through two primary segments: Pharmaceuticals and Medical Devices. Its pharmaceutical division addresses various therapeutic areas, including immunology, oncology, neuroscience, infectious diseases, cardiovascular, and metabolic diseases.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $155.00 on December 13th, 2023.
- Our designated price target stands at $190.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy JOHNSON & JOHNSON (JNJ) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
VRTX
VERTEX PHARMACEUTICALS INCORPORATED
(NASDAQ: VRTX)
Balfour Capital Group Researched Vertex Pharmaceuticals Incorporated (VRTX) on December 13th, 2023.
Vertex Pharmaceuticals Incorporated is a global biotechnology company dedicated to discovering, developing, manufacturing, and commercializing innovative therapies for serious diseases. The company is renowned for its transformative medicines, particularly in the field of cystic fibrosis (CF).
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $357.00 on December 13th, 2023.
- Our designated price target stands at $540.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy VERTEX PHARMACEUTICALS INCORPORATED (VRTX) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
